Absci Corporation (ABSI)

Absci is an AI-driven drug creation platform play, with analysts pricing in a long-duration bet on its generative AI and zero-shot protein design capabilities rather than near-term financials. The bull thesis rests entirely on platform partnerships and pipeline optionality, with 9 of 10 analysts rated Buy and a consensus target implying ~23% upside from current levels. The primary risk is a severe -81.8% YoY revenue decline, ongoing cash burn, and no visible path to profitability, leaving the stock highly vulnerable to sentiment shifts or partnership delays.

• New or expanded AI drug discovery partnership announcements that validate platform commercial utility and provide near-term revenue visibility.
• Publication of clinical or preclinical data from pipeline programs co-developed using Absci's generative AI platform, potentially in H2 2025.
• Improved quarterly revenue performance reversing the steep YoY decline, which could signal early platform monetization and re-rate the stock positively.

• Revenue collapsed -81.8% YoY, suggesting loss or restructuring of major partnership revenue; any further contract terminations could push the stock materially lower.
• Loss-making with a negative forward P/E of -17.1x and no earnings growth path — continued cash burn raises dilution risk, potentially pressuring existing shareholders by 10–20%+ if a capital raise is needed.
• High sentiment dependency: with 9 of 10 analysts rated Buy, there is limited room for further upgrades, and any negative pipeline readout or macro risk-off rotation could trigger rapid multiple compression given the speculative valuation.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →